Ensign Peak Advisors Inc Sells 109,239 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Ensign Peak Advisors Inc reduced its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 15.4% in the second quarter, according to its most recent filing with the SEC. The fund owned 599,550 shares of the medical equipment provider’s stock after selling 109,239 shares during the period. Ensign Peak Advisors Inc owned approximately 0.17% of Intuitive Surgical worth $266,710,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in Intuitive Surgical by 1.6% during the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after buying an additional 493,126 shares during the period. Price T Rowe Associates Inc. MD grew its position in Intuitive Surgical by 1.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock worth $5,726,102,000 after acquiring an additional 272,741 shares during the last quarter. Capital World Investors grew its position in Intuitive Surgical by 1.0% during the 1st quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock worth $2,907,079,000 after acquiring an additional 73,634 shares during the last quarter. Edgewood Management LLC increased its stake in Intuitive Surgical by 7.9% in the 4th quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock worth $1,731,016,000 after purchasing an additional 374,667 shares during the period. Finally, Jennison Associates LLC lifted its position in Intuitive Surgical by 4.6% in the first quarter. Jennison Associates LLC now owns 4,488,343 shares of the medical equipment provider’s stock valued at $1,791,253,000 after purchasing an additional 198,483 shares during the last quarter. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Trading Down 0.8 %

Intuitive Surgical stock opened at $486.20 on Friday. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $496.18. The stock has a fifty day simple moving average of $468.01 and a two-hundred day simple moving average of $424.86. The firm has a market cap of $172.46 billion, a price-to-earnings ratio of 87.76, a PEG ratio of 5.41 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. Intuitive Surgical’s revenue was up 14.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.18 EPS. On average, equities research analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. The Goldman Sachs Group initiated coverage on shares of Intuitive Surgical in a report on Thursday, May 30th. They issued a “buy” rating and a $500.00 target price on the stock. JPMorgan Chase & Co. increased their target price on shares of Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. BTIG Research raised their target price on Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a research note on Wednesday, August 28th. Piper Sandler upped their price target on Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Finally, Morgan Stanley increased their price objective on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $446.45.

Insider Activity at Intuitive Surgical

In other news, Director Craig H. Barratt sold 1,400 shares of the stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $641,382.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Craig H. Barratt sold 1,400 shares of the company’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $641,382.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the transaction, the senior vice president now directly owns 3,001 shares in the company, valued at approximately $1,461,006.84. The disclosure for this sale can be found here. Insiders have sold a total of 53,120 shares of company stock worth $25,528,753 over the last quarter. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.